Plasma mediators in patients with severe COVID-19 cause lung endothelial barrier failure

To the Editor:

Approximately 20% of symptomatic patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection progress to severe coronavirus disease 2019 (COVID-19) with critical hypoxaemia fulfilling the criteria of acute respiratory distress syndrome (ARDS). Consistent with the classic features of ARDS, severe COVID-19 is characterised by ground glass opacities on computed tomography imaging and diffuse alveolar damage post mortem [1], suggesting permeability-type lung oedema as driver of respiratory failure. Consistent with this concept, autopsy findings show severe lung endothelial injury in patients who succumbed to COVID-19 [2].

At present, the extent of endothelial barrier failure and its underlying mechanisms in COVID-19 remain unclear. While the occasional presence of viral particles in lung endothelial cells has been reported in autopic studies [2], endothelial cells are not thought to be infected directly in SARS [3]. Alternatively, endothelial barrier failure may be caused by barrier-disruptive mediators released from the infected airspace epithelium and the consecutive immune response. If so, these mediators and their barrier-disruptive effect should be recoverable from circulating blood plasma. Here, we provide proof-of-principle for this concept and report a screening platform for endothelial barrier regulation, that can be utilised to 1) identify pathological mediators and 2) screen for the therapeutic potential of barrier-stabilising compounds in COVID-19.

Citrate plasma was sampled as part of the prospective observational Pa-COVID-19 cohort study (ethics approval EA2/066/20) in 14 patients with moderate (hospitalised, no invasive ventilation; WHO severity score 3–4) and 19 with severe (high flow O2 or intubated and mechanically ventilated; WHO severity score 5–7) COVID-19. Plasma samples were diluted to 10% (v/v) in cell culture medium without FCS and tested for their ability to disrupt barrier integrity of primary human pulmonary microvascular endothelial cells (HPMEC, passage 4–7) monolayers by 1) electrical cell-substrate impedance sensing (ECIS Z-Theta, Applied BioPhysics), 2) measurement of trans-endothelial electrical resistance (TEER) using a REMS Auto Sampler (World Precision Instruments), and 3) immunofluorescence for endothelial VE-cadherin and F-actin. Plasma from 15 healthy donors (ethics approval EA2/075/15) served as control. Samples were probed for SARS-CoV-2 RNA by real-time RT-PCR. Human lung tissue from non-COVID-19 patients (ethics approval EA2/079/13) was probed for protein levels of VE-cadherin and occludin following stimulation with plasma for 24 h. Data are presented as mean±SEM. Different treatment groups were compared by Mann–Whitney U-test or two-way ANOVA followed by Tukey’s post hoc test. Statistical significance was assumed at $p<0.05$.

In contrast to healthy donor plasma, plasma from COVID-19 patients induced a rapid (within 1–2 h) and sustained (>6 h) increase in endothelial permeability of HPMEC monolayers (figure 1a and b). As shown by two methods, ECIS and TEER, the decrease in monolayer resistance after 6 h was more pronounced in plasma from patients with severe as compared to moderate disease. The barrier-disruptive effect of 10% severe COVID-19 plasma was comparable to that of 50 µmol·L$^{-1}$ platelet-activating factor, an established biological disruptor of the lung microvascular barrier. HPMEC monolayer disruption was similarly evident by immunofluorescence microscopy, demonstrating loss of junctional VE-cadherin and cortical actin.

FIGURE 1 Plasma of coronavirus disease 2019 (COVID-19) patients induces endothelial barrier failure. a) Barrier integrity of pulmonary microvascular endothelial cell monolayers assessed by electric cell impedance sensing (ECIS) in response to stimulation with 10% (v/v) plasma (at t=0 h) of healthy controls (number of samples/donors: 17/14), and moderate (25/14) or severe (22/16) COVID-19 patients. In cases of multiple samples from the same patient these were obtained at different time-points. Data are normalised to mean endothelial cell (EC) resistance in healthy donors. b) Trans-endothelial electrical resistance (TEER) response of EC monolayers to stimulation with 10% (v/v) plasma (at t=0 h) of healthy controls (7/7), and moderate (4/4), or severe (8/7) COVID-19 patients, with medium control and platelet activating factor as negative and positive controls. c) Representative immunofluorescence images of EC monolayers treated for 6 h with 10% (v/v) plasma of either healthy donors or severe COVID-19 patients stained for (left) VE-cadherin (cyan) or (centre) F-actin (green). Nuclei are shown in blue (DAPI). Gap area per cell (white in F-actin images) was identified by an automated segmentation algorithm (selecting pixels with zero values in both the F-Actin and VE-cadherin channel) using Fiji/MorpholibJ-Plugin, and was quantified for EC monolayers treated with plasma from healthy donors (7/7) or severe COVID-19 patients (7/7) (right). d) Representative western blots and quantification of VE-cadherin and occludin protein levels (normalised to healthy donors) in human lung samples from five donors treated for 24 h with plasma of three healthy donors or five severe COVID-19 patients. *: p≤0.05.
formation of actin stress fibres, and inter-endothelial gap formation in response to plasma from severe COVID-19 patients as compared to healthy controls (figure 1c). Exposure of human lung tissue to severe COVID-19 plasma caused loss of the junctional molecule occludin while changes in VE-cadherin protein levels did not reach statistical significance (figure 1d). All plasma samples, as well as cell lysates and supernatants from plasma-exposed HPMECs tested negative for SARS-CoV-2 RNA. Here, we demonstrate that plasma from COVID-19 patients induces robust barrier failure of the lung microvascular endothelium. This barrier-disruptive potential of plasma increased from moderate to severe disease, a finding that is in line with proteomic analyses demonstrating changes in inflammatory plasma biomarkers as a function of disease severity [4]. While this barrier-disruptive effect is per se likely not unique to COVID-19 and may be equally evident in other critically ill patients, the recent identification of a distinct biomarker signature in the plasma of COVID-19 patients, as compared to e.g. severe influenza infection [4], suggests the involvement of specific mediators or pathways in COVID-19-related endothelial barrier failure.

Treatment of healthy endothelial monolayers with plasma of COVID-19 patients was associated with significant endothelial gap formation and loss of junctional VE-cadherin in endothelial monolayers. Loss of junctional proteins was also evident in human lung tissue, although large scatter in expression levels resulted in considerable overlap between healthy and COVID-19-plasma treated human lung tissue. In line with the clinical course of patients following SARS-CoV-2 infection, these findings indicate substantial biological variability of the host tissue both at baseline and in response to stimulation with COVID-19 plasma. Notably, these effects were not attributable to a direct action of SARS-CoV-2 on the endothelium, as demonstrated by the absence of viral RNA. Our findings provide proof-of-principle for the concepts that 1) endothelial injury and barrier failure are characteristic features of severe COVID-19, 2) are caused by endogenous plasma factors, rather than direct injury by viral infection, and 3) may drive the progression from mild disease to critical ARDS [2, 5]. Notably, endothelial activation may not be restricted to the regulation of vascular permeability, but could also contribute to other clinical manifestations of COVID-19 associated vasculopathies, such as microthrombosis and vascular inflammation.

The present work in conjunction with our recent proteome analyses in COVID-19 plasma [4] provides for a versatile platform to screen for the relevance of individual plasma mediators of endothelial permeability in high throughput mode. To this end, correlative changes in plasma mediators and barrier failure as a function of disease severity may guide the identification of key signalling mechanisms. Of equal relevance, this platform allows to screen for the prophylactic or therapeutic effectiveness of drugs with demonstrated barrier-protective action [4]. Importantly, the unique time profile of COVID-19 with a slow progression from symptom onset to mild, moderate, and ultimately severe disease provides a model scenario for the application of barrier-stabilising adjunctive therapies. We therefore propose that pharmacological stabilisation of the endothelial barrier should be considered as a third pillar for the treatment of COVID-19 in addition to anti-virals and immunomodulators.

Laura Michalick1, Sarah Weidenfeld1, Benjamin Grimmer1, Diana Fatykhova2, Philip Daniel Selymou1, Felix Behrens1,2, Melanie Dohnert1, Markus C. Bruck3, Sabrina Schulz1, Elisa Thomasch3, Szandor Simmons4, Holger Müller-Redetzky5, Norbert Sutter5, Florian Kuth6, Jens Neudecker7, Mario Toennies7, Torsten T. Bauer7, Stephan Eggeling8, Victor Max Corman9,10, Andreas C. Hocke2,5, Martin Wittenrath2,5,14, Stefan Hippenstiel2,5,14 and Wolfgang M. Kuebler1,5,11,12,13,14

1Institute of Physiology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany. 2Dept of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany. 3Dept of Surgery and Thoracic Surgery, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany. 4Max Delbrück Center for Molecular Medicine, Berlin, Germany. 5German Center for Lung Research (DZL), Germany. 6Dept of General, Visceral, Vascular and Thoracic Surgery, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany. 7Lungenklinik Heckeshorn, HELIOS Klinikum Emil von Behring, Berlin, Germany. 8Vivantes Netzwerk für Gesundheit, Klinikum Neukölln, Klinik für Thoraxchirurgie, Berlin, Germany. 9Institute of Virology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany. 10German Centre for Infection Research (DZIF), Germany. 11The Keenan Research Centre for Biomedical Science, St. Michael’s Hospital, Toronto, ON, Canada. 12Depts. of Surgery and Physiology, University of Toronto, Toronto, ON, Canada. 13German Centre for Cardiovascular Research (DZHK), Germany. 14These authors contributed equally to this study.

Correspondence: Wolfgang M. Kuebler, Institute of Physiology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. E-mail: wolfgang.kuebler@charite.de

Received: 18 June 2020 | Accepted: 11 Oct 2020

Acknowledgements: The authors thank the Advanced Medical Bioimaging Core Facility (AMBIO) of Charité—Universitätsmedizin Berlin (Berlin, Germany) for the support in acquisition of the imaging data.

https://doi.org/10.1183/13993003.02384-2020
Author contributions: L. Michalick, A.C. Hocke, M. Witzenrath and W.M. Kuebler conceived the study; L. Michalick, S. Weidenfeld, B. Grimmer, D. Fathykhova, P.D. Solymosi, M. Dohmen, M.C. Brack, V.M. Corman and S. Schulz performed experiments and analysed the data; H. Müller-Redetzky, F. Kurth, N. Suttorp, F. Behrens, E. Thomash, S. Simmons, J. Neudecker, M. Toennies, T.T. Bauer and S. Eggeling provided and collected samples; F. Kurth and M. Witzenrath led the clinical study; L. Michalick, A.C. Hocke, M. Witzenrath, S. Hippenstiel and W.M. Kuebler wrote the manuscript; all authors revised and approved the manuscript.

Conflict of interest: S. Weidenfeld has nothing to disclose. B. Grimmer has nothing to disclose. D. Fathykhova has nothing to disclose. P.D. Solymosi has nothing to disclose. F. Behrens has nothing to disclose. M. Dohmen has nothing to disclose. M.C. Brack has nothing to disclose. F. Kurth has nothing to disclose. H. Müller-Redetzky has nothing to disclose. N. Suttorp has nothing to disclose. E. Thomasch has nothing to disclose. S. Simmons has nothing to disclose. F. Kurth has nothing to disclose. J. Neudecker has nothing to disclose. M. Toennies has nothing to disclose. T.T. Bauer has nothing to disclose. S. Eggeling has nothing to disclose. V.M. Corman has nothing to disclose. A.C. Hocke has nothing to disclose. W.M. Kuebler reports grants and personal fees from Actelion, Bayer Health Care, Biotest, Boehringer Ingelheim, Noxxon, Pantherma, Silence Therapeutics and Vaxxilon, grants from Quark Pharma and Takeda Pharma, personal fees from Aaptarion, AstraZeneca, Berlin Chemie, Chiesi, GlaxoSmithKline, Novartis, Sinoxa and Teva, outside the submitted work; and has a patent “Means for inhibiting the expression of ANG2 US8829179B2” issued. S. Hippenstiel has nothing to disclose. W.M. Kuebler reports grants from Ministry of Education and Research (BMBF), German Research Foundation (DFG), German Centre for Cardiovascular Research (DZHK) and Canadian Institutes for Health Research (CIHR), during the conduct of the study. L. Michalick has nothing to disclose.

Support statement: A.C. Hocke and S. Hippenstiel are supported by Berlin University Alliance GC2 Global Health (Corona Virus Pre Exploration Project), BMBF (RAPID, alvBarriere-COVID-19, PROVID), DFG (SFB-TR 84), BIH, Charite JF and Charité-Zeiss MultiDim; M. Witzenrath is supported by DFG (SFB-TR84) and BMBF (CAPSyS-FKZ, Phage4Cure-FKZ, SYMPATH, PROVID); W.M. Kuebler is supported by grants-in-aid from the BMBF (SYMPATH, PROVID), the DFG (DFG 1218/9-1, 1218/11-1, SFB-TR84), the German Centre for Cardiovascular Research (DZHK), and the Canadian Institutes for Health Research (CIHR). Funding information for this article has been deposited with the Crossref Funder Registry.

References